Aggressive lymphoma: news on ASH 2014

This article reviews the most important news at American Society of Hematology (ASH) 2014 for the clinician. A validated risk model for central nervous system (CNS) relapse after rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) defined a low, intermediate, and a high risk group. The latter with a CNS-relapse risk of 12 %. Interim positron emission tomography (PET) imaging and different treatment strategies for positive disease were highly prognostic for an unfavorable prognosis. However, the salvage strategies for these patients were not successful. The role of radiotherapy was clarified in a randomized trial of non-bulky stage I or II disease. It was not possible to demonstrate an event-free (EFS) and overall (OS) survival benefit for radiation after 4–6 R-CHOP cycles. Unfortunately ofatumomab was not superior to rituximab in combination with DHAP in relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Source: Memo - Magazine of European Medical Oncology - Category: Cancer & Oncology Source Type: research

Related Links:

Publication date: Available online 30 August 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Zuzan Cayci, Kerem Ozturk, Celalettin Ustun, Aazim K. Omer, Erhan Dincer, Zohar Sachs, Bruce A. Peterson, Michael A. LindenAbstractSarcoidosis has been shown to be associated with increased risk of development of several malignancies including lymphomas. On the other hand, “sarcoid-like reactions” in the absence of other clinical signs of sarcoidosis, have also been described in patients who had been treated with chemotherapy for a wide variety of malignancies. In this article, we report 3 cases who had PET...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Authors: Kitajima K, Okada M, Yoshihara K, Tokugawa T, Sawada A, Yoshihara S, Tamaki H, Fujimori Y, Ueda S, Kawamoto H, Taniguchi J, Yamakado K Abstract Objectives: To examine the prognostic value of interim 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) findings after 2-4 cycles of rituximab, plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with diffuse large B-cell lymphoma (DLBCL) receiving standardized treatment. Results: After a median 3.36 years (range 0.33 to 9.14 years), 24 of the 80 patients had documented relapse. In Interim-PET fin...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
A promising and expensive type of immunotherapy, called CAR T-cell therapy, is now covered by Medicare. This news may affect mesothelioma patients in the future. Chimeric antigen receptor T-cell, or CAR T-cell, therapy involves the laboratory reprogramming of a patient’s T cells, which are a type of white blood cell responsible for protecting the body against infection and disease. The T cells are genetically modified to better recognize and attack cancer. The U.S. Food and Drug Administration has approved the immunotherapy procedure for non-Hodgkin lymphoma and B-cell precursor acute lymphoblastic leukemia. It is...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
The objective of this review was to determine whether in previously untreated adults with HL (all stages) receiving first-line therapy, interim PET scan results (i.e. a positive or a negative result) can distinguish between those with a poor prognosis and those with a better prognosis, and thereby predict survival in each group.How many studies were included? What was included and what was excluded?We included twenty-three studies in total, in this review. In all studies, interim PET was conducted during first-line therapy and after two, three, and/or four cycles of chemotherapy in adults with HL (all stages). We included ...
Source: Cochrane News and Events - Category: Information Technology Authors: Source Type: news
CONCLUSIONS: This review provides moderate-certainty evidence that interim PET scan results predict OS, and very low-certainty evidence that interim PET scan results predict progression-free survival in treated individuals with HL. This evidence is primarily based on unadjusted data. More studies are needed to test the adjusted prognostic ability of interim PET against established prognostic factors. PMID: 31525824 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Tags: Cochrane Database Syst Rev Source Type: research
ConclusionsBTZ loaded Gly4-PLA NPs apoptotic index was found to be much higher than BTZ but lesser than BTZ loaded FA-Gly4-PLA against breast cancer cell lines (MDA-MB-231). ROS intracellular assessment assay indicated that BTZ and BTZ loaded FA-Gly4-PLA NPs exhibited higher ROS production. Conclusively, the BTZ loaded FA-Gly4-PLA NPs were able to encapsulate more BTZ than BTZ loaded Gly4-PLA NPs and were found to be more effective as per asin vitro anti-cancer effect is concerned.
Source: Pharmaceutical Research - Category: Drugs & Pharmacology Source Type: research
This study investigated whether a radiomic analysis of pretreatment 18F-FDG PET can predict prognosis in patients with Hodgkin lymphoma (HL). Methods Forty-two patients who were diagnosed as having HL and underwent pretreatment 18F-FDG PET scans were retrospectively enrolled. For each patient, we extracted 450 radiomic features from PET images. The prognostic significance of the clinical and radiomic features was assessed in relation to progression-free survival (PFS) and overall survival (OS). Receiver operating characteristic curve, Cox proportional hazards regression, and Kaplan-Meier analyses were performed to exami...
Source: Clinical Nuclear Medicine - Category: Nuclear Medicine Tags: Original Articles Source Type: research
We present one such case of a 40-year-old married man who underwent PET/CT scan for staging workup of lymphoma and revealed this rare entity incidentally without any other testicular pathology.
Source: Clinical Nuclear Medicine - Category: Nuclear Medicine Tags: Interesting Images Source Type: research
We report a case of a 75-year-old man with concomitant metastatic prostate cancer and progressive follicular lymphoma and the utility of molecular imaging in differentiating these 2 conditions. 18F-FDG PET/CT can offer accurate staging in many cancers, although its role in prostate cancer is limited. The role of 18F-DCFPyL (PSMA) PET/CT in prostate cancer is evolving and has been demonstrated to have a higher sensitivity than conventional bone scan and CT scan. Together, FDG and PSMA PET/CT studies may offer a noninvasive approach to individually characterize concomitant malignancies, aiding optimization of management and follow-up.
Source: Clinical Nuclear Medicine - Category: Nuclear Medicine Tags: Interesting Images Source Type: research
Discussion Drawing conclusions on the causation of adverse health effects by environmental chemicals can have important societal consequences, leading to policy-making which can control, limit or even prevent the exposure to the pollutant through regulation and litigation. There are critical lessons to be learned from the Monsanto saga. The whole process of evidence-informed policy-making is under threat. The case of glyphosyte is by no means over; further research is needed to cover the knowledge gaps, but this should be done independently and with full transparency. The IARC Monographs provide the scientific evaluation ...
Source: Scandinavian Journal of Work, Environment and Health - Category: Occupational Health Tags: Commentary Source Type: research
More News: Cancer & Oncology | Hematology | Lymphoma | PET Scan | Prednisone | Rituxan